US4970075A
(en)
*
|
1986-07-18 |
1990-11-13 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL119660A
(en)
*
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
IL109944A
(en)
*
|
1993-07-01 |
1998-12-06 |
Euro Celtique Sa |
Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP2036558A3
(en)
*
|
1993-10-07 |
2010-04-28 |
Euro-Celtique S.A. |
Orally administrable opioid formulations having extended duration of effect
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
US5484608A
(en)
*
|
1994-03-28 |
1996-01-16 |
Pharmavene, Inc. |
Sustained-release drug delivery system
|
ES2097087B1
(es)
*
|
1994-08-01 |
1997-12-16 |
Univ Sevilla |
Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
JPH1050306A
(ja)
*
|
1996-07-31 |
1998-02-20 |
Toyota Autom Loom Works Ltd |
水素吸蔵合金電極の製造方法
|
PL193273B1
(pl)
*
|
1997-12-22 |
2007-01-31 |
Euro Celtique Sa |
Postać dawkowania doustnego
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
WO2000016776A1
(fr)
*
|
1998-09-18 |
2000-03-30 |
Takeda Chemical Industries, Ltd. |
Preparations a administrer par voie buccale a liberation lente
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
KR101476574B1
(ko)
|
1999-10-29 |
2014-12-24 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
CN1423559A
(zh)
|
2000-02-08 |
2003-06-11 |
欧罗赛铁克股份有限公司 |
包含阿片样激动剂和拮抗剂的控释组合物
|
EP1935421A1
(en)
|
2000-02-08 |
2008-06-25 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
MXPA03003895A
(es)
*
|
2000-10-30 |
2003-07-28 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada.
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
BR0205721A
(pt)
*
|
2001-07-06 |
2003-09-30 |
Endo Pharmaceuticals Inc |
Formulações de oximorfona de liberação controlada
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
WO2003004033A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Penwest Pharmaceuticals Company |
Sustained release formulations of oxymorphone
|
US7943173B2
(en)
|
2001-07-18 |
2011-05-17 |
Purdue Pharma L.P. |
Pharmaceutical combinations of oxycodone and naloxone
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030091635A1
(en)
*
|
2001-09-26 |
2003-05-15 |
Baichwal Anand R. |
Opioid formulations having reduced potential for abuse
|
CA2478523A1
(en)
*
|
2002-04-05 |
2003-10-16 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
GB0209265D0
(en)
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
CN1665482A
(zh)
*
|
2002-04-29 |
2005-09-07 |
阿尔扎公司 |
羟可待酮控制输送给药的方法和剂型
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
IL165361A0
(en)
*
|
2002-05-31 |
2006-01-15 |
Alza Corp |
Dosage forms and compositions for osmotic deliveryof variable dosages of oxycodone
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US8840928B2
(en)
*
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
CA2491572C
(en)
*
|
2002-07-05 |
2010-03-23 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
US20050020613A1
(en)
*
|
2002-09-20 |
2005-01-27 |
Alpharma, Inc. |
Sustained release opioid formulations and method of use
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
SI2218448T1
(sl)
|
2002-12-13 |
2016-01-29 |
Durect Corporation |
Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
EP1479381A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Euro-Celtique S.A. |
Pharmaceutical dosage form comprising a solid solution
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
EP2298303A1
(en)
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
US20050074493A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Mehta Atul M. |
Extended release formulations of opioids and method of use thereof
|
ES2515092T3
(es)
|
2003-12-11 |
2014-10-29 |
Sunovion Pharmaceuticals Inc. |
Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
|
TWI365880B
(en)
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
JP2007530684A
(ja)
*
|
2004-03-30 |
2007-11-01 |
ユーロ−セルティーク エス.エイ. |
吸着剤と逆作用薬とを含有する不正使用防止投与剤型
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
US20050266082A1
(en)
*
|
2004-05-26 |
2005-12-01 |
Patel Satishkumar A |
Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
DK1765292T3
(en)
|
2004-06-12 |
2018-01-02 |
Collegium Pharmaceutical Inc |
ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
|
US9308164B2
(en)
*
|
2004-06-30 |
2016-04-12 |
Sovereign Pharmaceuticals, Llc |
Hyoscyamine dosage form
|
GB2418854B
(en)
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
KR101351771B1
(ko)
|
2004-09-17 |
2014-02-17 |
듀렉트 코퍼레이션 |
바람직하게 saib와 같은 당 에스테르를 포함하는지속적인 국소 마취제 조성물
|
TWI369203B
(en)
|
2004-11-22 |
2012-08-01 |
Euro Celtique Sa |
Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
|
AU2006208627B8
(en)
*
|
2005-01-28 |
2009-08-13 |
Mundipharma Pty Limited |
Alcohol resistant dosage forms
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
US20090214640A1
(en)
*
|
2005-03-04 |
2009-08-27 |
Intelgenx Cporp. |
Delayed release pharmaceutical oral dosage form and method of making same
|
MY148074A
(en)
*
|
2005-05-10 |
2013-02-28 |
Novartis Ag |
Pharmaceutical compositions comprising imatinib and a release retardant
|
ES2344313T3
(es)
*
|
2005-06-09 |
2010-08-24 |
Euro-Celtique S.A. |
Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
|
TWI366460B
(en)
|
2005-06-16 |
2012-06-21 |
Euro Celtique Sa |
Cannabinoid active pharmaceutical ingredient for improved dosage forms
|
WO2007002597A2
(en)
|
2005-06-27 |
2007-01-04 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
EP1813276A1
(en)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
US20070281016A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and surfactant
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
HUE032156T2
(en)
|
2006-06-19 |
2017-09-28 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical preparations
|
EP2068840A2
(en)
*
|
2006-07-21 |
2009-06-17 |
LAB International SRL |
Hydrophobic abuse deterrent delivery system
|
CN101528269A
(zh)
*
|
2006-08-16 |
2009-09-09 |
奥斯拜客斯制药有限公司 |
阿片样物质止痛剂的制备和应用
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
PT2117521E
(pt)
|
2006-11-03 |
2012-09-10 |
Durect Corp |
Sistemas de administração transdérmica que compreendem bupivacaína
|
US20080220064A1
(en)
*
|
2006-12-06 |
2008-09-11 |
Ramesh Ketkar Anant |
Extended release matrix formulations of morphine
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
US8202542B1
(en)
|
2007-05-31 |
2012-06-19 |
Tris Pharma |
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
AU2008347158B8
(en)
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
US20100003322A1
(en)
*
|
2008-07-03 |
2010-01-07 |
Lai Felix S |
Enteric coated hydrophobic matrix formulation
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
ES2706407T3
(es)
|
2009-03-10 |
2019-03-28 |
Euro Celtique Sa |
Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
|
FR2946533A1
(fr)
|
2009-06-12 |
2010-12-17 |
Ethypharm Sa |
Reduction des fluctuations plasmatiques d'opioides.
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8927025B2
(en)
|
2010-05-11 |
2015-01-06 |
Cima Labs Inc. |
Alcohol-resistant metoprolol-containing extended-release oral dosage forms
|
CA2991216C
(en)
|
2010-12-22 |
2020-04-28 |
Purdue Pharma L.P. |
Encased tamper resistant controlled release dosage forms
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
JP6279547B2
(ja)
|
2012-04-17 |
2018-02-14 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法
|
TW201639855A
(zh)
|
2012-07-16 |
2016-11-16 |
羅德科技公司 |
改良之類鴉片合成方法
|
US10316042B2
(en)
|
2012-07-16 |
2019-06-11 |
Rhodes Technologies |
Process for improved opioid synthesis
|
BR112015017451B1
(pt)
|
2013-02-05 |
2023-01-10 |
Purdue Pharma L.P. |
Formulações farmacêuticas resistentes à violação
|
EP2983468A4
(en)
|
2013-03-15 |
2016-09-07 |
Durect Corp |
COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
EP3878445A3
(en)
|
2013-06-05 |
2021-10-27 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
AU2014295042B2
(en)
|
2013-07-23 |
2017-03-30 |
Mundipharma Pty Limited |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
GB2517000B
(en)
|
2013-08-02 |
2018-05-09 |
Johnson Matthey Plc |
Process for the synthesis of oxymorphone alkaloid and oxymorphone salts
|
ES2672795T3
(es)
|
2014-01-15 |
2018-06-18 |
Rhodes Technologies |
Proceso para la síntesis mejorada de oximorfona
|
AU2015207733A1
(en)
|
2014-01-15 |
2016-07-14 |
Rhodes Technologies |
Process for improved oxycodone synthesis
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
CA3003950C
(en)
|
2015-10-23 |
2020-05-12 |
Kashiv Pharma Llc |
Enhanced abuse-deterrent formulations of oxycodone
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
EP3703724A1
(en)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
WO2021146215A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|
KR20230000634U
(ko)
|
2021-09-16 |
2023-03-23 |
장상환 |
분리가능한 쇠스랑
|